SAFC Expands Fermentation Capabilities with Upgrade of Israel Site
SAFC (St. Louis, MO), a member of the Sigma-Aldrich Group, has announced a $29-million investment to significantly expand its drug substance capabilities in high-potency biologics at the Sigma-Aldrich facility in Jerusalem, Israel
SAFC (St. Louis, MO), a member of the Sigma-Aldrich Group, has announced a $29-million investment to significantly expand its drug substance capabilities in high-potency biologics at the Sigma-Aldrich facility in Jerusalem, Israel. The site enhancement will enable SAFC Pharma to provide process development and cGMP manufacturing to customers requiring large-scale, high-potency, toxic, or hazardous large molecule high potent active pharmaceutical ingredients (HPAPI).
The expansion, scheduled for completion in the first quarter of 2009, will focus production on secondary metabolites, cytotoxins, and large-molecule proteins. A 30,000-sq. ft. area of the new facility has been designed to be Biosafety Level 2 compliant, enabling manipulation of human pathogens. The new capabilities will expand SAFC Pharma’s HPAPI offering to include fermentation-derived HPAPI manufacturing, complementing the multistep organic synthesis flagship facility at its Madison, WI, location.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
